These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18653459)

  • 1. Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence.
    Waheed AA; Ablan SD; Soheilian F; Nagashima K; Ono A; Schaffner CP; Freed EO
    J Virol; 2008 Oct; 82(19):9776-81. PubMed ID: 18653459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
    Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
    PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Neil SJ; Zang T; Bieniasz PD
    Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
    Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
    Fritz JV; Tibroni N; Keppler OT; Fackler OT
    Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
    Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
    J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
    Gupta RK; Hué S; Schaller T; Verschoor E; Pillay D; Towers GJ
    PLoS Pathog; 2009 May; 5(5):e1000443. PubMed ID: 19461879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions.
    Skasko M; Wang Y; Tian Y; Tokarev A; Munguia J; Ruiz A; Stephens EB; Opella SJ; Guatelli J
    J Biol Chem; 2012 Jan; 287(1):58-67. PubMed ID: 22072710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane raft association of the Vpu protein of human immunodeficiency virus type 1 correlates with enhanced virus release.
    Ruiz A; Hill MS; Schmitt K; Stephens EB
    Virology; 2010 Dec; 408(1):89-102. PubMed ID: 20880565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
    Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
    PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction.
    Schmidt S; Fritz JV; Bitzegeio J; Fackler OT; Keppler OT
    mBio; 2011; 2(3):e00036-11. PubMed ID: 21610122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.
    Dubé M; Roy BB; Guiot-Guillain P; Mercier J; Binette J; Leung G; Cohen EA
    J Virol; 2009 May; 83(9):4574-90. PubMed ID: 19244337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
    Goffinet C; Homann S; Ambiel I; Tibroni N; Rupp D; Keppler OT; Fackler OT
    J Virol; 2010 Apr; 84(8):4089-94. PubMed ID: 20147395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity.
    Waheed AA; Kuruppu ND; Felton KL; D'Souza D; Freed EO
    PLoS One; 2014; 9(10):e111628. PubMed ID: 25360760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
    Dotson D; Woodruff EA; Villalta F; Dong X
    J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tethered virions are intermediates in the assembly and release of HIV-1 particles.
    Karetnikov A; Suomalainen M
    Virology; 2010 Nov; 407(2):289-95. PubMed ID: 20850859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.
    Bolduan S; Votteler J; Lodermeyer V; Greiner T; Koppensteiner H; Schindler M; Thiel G; Schubert U
    Virology; 2011 Jul; 416(1-2):75-85. PubMed ID: 21601230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
    Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.